Richard B. Warren

Bimekizumab versus Secukinumab in Plaque Psoriasis

Kristian Reich, Richard B. Warren, Mark Lebwohl et al. · New England Journal of Medicine · 2021 · 368 citations

Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Richard B. Warren, Catherine Smith, Zenas Z N Yiu et al. · Journal of Investigative Dermatology · 2015 · 366 citations

British Association, Clinical Epidemiology, Clinical Dermatology +6

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

April W. Armstrong, Melinda Gooderham, Richard B. Warren et al. · Journal of the American Academy of Dermatology · 2022 · 316 citations · Full text

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

Kristian Reich, Kim Papp, Andrew Blauvelt et al. · The Lancet · 2021 · 276 citations

Systemic Treatment, Clinical Trials, Bimekizumab Versus Ustekinumab +6

Clinical and genetic differences between pustular psoriasis subtypes

Sophie Twelves, Alshimaa Mostafa, Nick Dand et al. · Journal of Allergy and Clinical Immunology · 2018 · 259 citations · Full text